Search other companies ESG researched by sustainAX here
Zenicor – ESG risk research and ESG rating
We at sustainAX have ESG risk researched and ESG risk rated Zenicor and our clients can access the reseach on their Bloomberg terminals.
Zenicor is in the materiality based sector of TECHNOLOGY HARDWARE AND EQUIPMENT, TELECOMMUNICATION SERVICES.
Our ESG risk research of Zenicor
Our approach to ESG research is fundamental, that means that we have studied all relevant publications by Zenicor and combined this with fundamental understanding of ESG challenges and risks of different activities and for the TECHNOLOGY HARDWARE AND EQUIPMENT, TELECOMMUNICATION SERVICES sector. This makes us well placed to estimate the ESG risks of Zenicor. We have published a 33 pages ESG research report on Zenicor with a conclusion highlighting the most important residual risks, a section suggesting how it should be integrated in investment decisions and a list of all the questions we think should be asked to Zenicor.
More about our ESG risk research here: https://www.sustainax.com/index.php/esg-research/
AGGREGATED ESG RISK RATING* for Zenicor:
20-40 of 100
High risk
Where 100 is the lowest ESG risk and 0 is the highest risk.
*The ESG, E, S and G risk rating ranges indicate to what degree Zenicor has addressed and mitigated their material ESG risks according to the sustainAX materiality matrix. sustainAX’ clients have access to the exact ESG risk rating.
**The weight in the aggregated ESG rating
Environmental RISK RATING* and WEIGHT** for Zenicor:
0-20 of 100 – Very High risk
32.66 %
Social RISK RATING* and WEIGHT** for Zenicor:
40-60 of 100 – Middle risk
33.65 %
Governance RISK RATING* and WEIGHT** for Zenicor:
40-60 of 100 – Middle risk
33.68 %
What the company say about themselves:
Zenicor Medical Systems AB is a Swedish medical technology company that is a leader in early diagnosis of arrhythmias and stroke prevention for healthcare. The company was founded in 2003 and has thus been active in the field for 20 years, which means that we are one of the pioneers leading the development in the diagnosis of atrial fibrillation. Zenicor works actively to develop the chain of care for early diagnosis. Together with researchers and healthcare professionals, Zenicor has developed a complete solution – Zenicor ECG – which enables a simple and cost-effective method for finding and diagnosing atrial fibrillation and other heart rhythm disorders. - Zenicor conducts its own research and development of systems and products with the objective of ensuring continued internationally competitive solutions in the long term. Sales, training, technical support and service are primarily handled by Zenicor's own employees. Manufacturing takes place at the company's Swedish partner Orbit One.
Are you interested in the ESG research and ESG rating?
If you are interested in the ESG risk research and ESG risk rating of Zenicor, contact us at sustainAX!
© Copyright SustainAX AB and www.sustainax.com, 2024. Please note that by accessing and using the SustainAX AB website, you are consenting to comply with our Terms of Use and acknowledging the acceptance of any inherent risks. The content provided on this site is available for your non-commercial, non-competitive use, specifically for the purposes of understanding companies’ environmental, social, and governance (ESG) risks. Should you wish to employ our information within a professional capacity, it is incumbent upon you to secure the appropriate licensing rights from us. Be aware that any form of unauthorised data extraction or the systematic electronic harvesting of our content is expressly forbidden.